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Abstract
Background Mouse models are useful for studying ci-
garette smoke (CS)-induced chronic pulmonary pathologies
such as lung emphysema. To enhance translation of large-
scale omics data from mechanistic studies into patho-
physiological changes, we have developed computational
tools based on reverse causal reasoning (RCR).
Objective In the present studywe applied a systems biology
approach leveraging RCR to identify molecular mechanistic
explanations of pathophysiological changes associated with
CS-induced lung emphysema in susceptible mice.
Methods The lung transcriptomes of five mouse models
(C57BL/6, ApoE2/2, A/J, CD1, and Nrf22/2) were ana-
lyzed following 5–7 months of CS exposure.
Results We predicted 39 molecular changes mostly re-
lated to inflammatory processes including known key
emphysema drivers such as NF-jB and TLR4 signaling,
and increased levels of TNF-a, CSF2, and several inter-
leukins. More importantly, RCR predicted potential
molecular mechanisms that are less well-established, in-
cluding increased transcriptional activity of PU.1, STAT1,
C/EBP, FOXM1, YY1, and N-COR, and reduced protein
abundance of ITGB6 and CFTR. We corroborated several
predictions using targeted proteomic approaches, demon-
strating increased abundance of CSF2, C/EBPa, C/EBPb,
PU.1, BRCA1, and STAT1.
Conclusion These systems biology-derived candidate
mechanisms common to susceptible mouse models may en-
hance understanding of CS-induced molecular processes
underlying emphysema development in mice and their
relevancy for human chronic obstructive pulmonary disease.
Keywords Emphysema  Cigarette smoke 
Systems biology  Mouse models  Gene expression 
Molecular mechanisms
Introduction
Chronic obstructive pulmonary disease (COPD) is a com-
plex pulmonary disorder primarily induced by cigarette
smoking and characterized by poorly or not reversible
airflow obstruction. The three major clinical manifestations
of COPD are emphysema, chronic bronchitis and small
airway diseases [1, 2]. A hallmark of the disease is chronic
inflammation in the airways and lungs, which together with
protease/anti-protease imbalance, apoptosis and oxidative
stress contributes to the progressive tissue damage under-
lying COPD pathophysiology [3, 4]. Increasing severity of
the disease, evidenced by more pronounced airflow ob-
struction, is measured by spirometry and graded according
to the Global Initiative for chronic obstructive lung disease
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(GOLD) criteria (grades I–IV). Grades I and II represent
mild and usually early stages of COPD, while grades III
and IV correspond to progressively more severe disease
stages [2].
Our understanding of emphysema and COPD patho-
genesis has evolved considerably over the past 50 years;
however, we still have very limited knowledge regarding
the complex molecular mechanisms that drive the patho-
logical changes. Although [90 % of COPD patients are
smokers, only 20 % of smokers develop COPD [5, 6] with
the underlying reasons for this being complex but likely
involving genomic variation as an important determinant of
disease susceptibility [7]. In mice, CS-related pulmonary
changes also have a genetic component, evidenced by the
fact that different strains display varying susceptibility to
CS exposure and emphysema development [8–10]. It has
been proposed that differential susceptibility or resistance
of these strains to CS exposure may be due to the varying
degree of activation of signaling pathways such as nuclear
factor (NF)-jB, p38 mitogen-activated protein kinase or
histone deacetylase (HDAC)2 [8–10]. In addition, genetic
or pharmacological manipulation resulted in identification
of many key molecules associated with murine CS-induced
emphysema [11]. Several groups, using knock-out and
transgenic mice, have clearly demonstrated the importance
of multiple genes and pathways, including chemokine/cy-
tokine receptors (e.g. C–C motif receptor (CCR)1, CCR5,
CCR6 [12–14]), metalloproteinase enzymes (e.g. MMP-9/
12 [15]), cytokines (e.g. interleukin (IL)-1b, IL-18 [16,
17]), and transcription factors (TFs) such as NF-jB [18],
nuclear factor erythroid 2-related factor 2 Nrf2 [19] or
activator protein (AP)-1 [20]).
Although these studies have increased our understanding
of emphysema development and progression, they have
several potential limitations with respect to identification of
precise molecular mechanisms. For example, the ap-
proaches were mostly focused on single gene analysis or
characterization of cellular, inflammatory or histopatho-
logical changes without attempting a more comprehensive
mechanistic investigation using multi-omics technologies.
Remarkably, only a few studies have investigated global
gene expression profiles associated with the development or
progression of murine CS-induced emphysema [19, 21–24].
Considering that COPD is a highly heterogeneous and
polygenic disease, a more comprehensive and powerful
approach that translates these large-scale data sets into
pathophysiological changes is essential to enhance under-
standing of the molecular mechanisms that induce alveolar
destruction and subsequent emphysema. For instance, we
recently applied Reverse Engineering and Forward
Simulation (REFSTM) technology to identify key molecular
drivers of emphysema in A/J mice by integrating the whole
genome expression data and COPD-relevant endpoints [25].
In the current study, we comprehensively investigated
the lung transcriptomes leveraging the RCR [26] method-
ology to evaluate molecular mechanisms underlying
emphysematous changes. Among the 39 predictions that
were common to the five strains/genotypes investigated, we
identified mechanisms known to be associated with em-
physema including NF-jB signaling, Toll-like receptor
(TLR4) signaling, and increased protein abundance of in-
flammatory mediators such as tumor necrosis factor (TNF)-
a, colony stimulating factor 2 (granulocyte–macrophage)
(CSF2), as well as several interleukins. More importantly,
we predicted a series of mechanisms for which a role in
emphysema development is not yet well documented, e.g.
transcriptional activity of spleen focus forming virus
(SFFV) proviral integration oncogene (SFPI1, aka.PU.1),
signal transducers and activators of transcription (STAT)-1,
CCAAT/enhancer-binding protein (C/EBP), forkhead box
M1 (FOXM1), Yin and Yang (YY)-1, nuclear receptor
corepressor (N-COR), increased protein expression of IL-
17, or decreased protein expression of integrin Beta-6
(ITGB6) and cystic fibrosis transmembrane conductance
regulator (CFTR). The present study contributes to a better
understanding of the specific CS-induced molecular pro-
cesses underlying emphysema development in mice by
elucidating novel effectors implicated in disease progres-
sion, which could also be relevant in human COPD.
Materials and methods
Transcriptomics data sets
Transcriptomics data sets were derived from four mouse
CS-inhalation studies: C57BL/6 [27], apolipoprotein E–
deficient (ApoE-/-) C57BL/6 mice [28], A/J mice [25],
CD1 and nuclear factor erythroid 2-related factor 2-defi-
cient CD1 mice (Nrf2-/-) [29]. The exposure studies, three
of which have been published in detail previously, were
conducted in Philip Morris Research Laboratories at dif-
ferent times and locations under similar mainstream CS
exposure protocols (Table 1). RNA was isolated from either
whole lung (C57BL/6, ApoE-/-, Nrf2-/-, and CD1 mice)
or lung parenchyma by laser capture microdissection (A/J
and ApoE-/- mice). In case of C57BL/6 mice, genome-
wide expression profiling of whole lung was conducted at 1,
3, 5, and 7 months in the sham (air exposed) and CS groups
(for experimental details, see below). Affymetrix CEL files
that passed the quality check were used for further data
processing and are publicly available: Gene Expression
Omnibus (GSE18344) for the CD1/Nrf2-/- mice, Array
Express (E-MTAB-1390) for the C57BL/6 ApoE-/- mice,
Array Express (E-MTAB-1426) for the A/J mice, and Array
Express (E-MTAB-2756) for the C57BL/6 mice.
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Animals and CS exposure
Care and use of the mice was in conformity with the
American Association for Laboratory Animal Science
Policy on the Humane Care and Use of Laboratory Ani-
mals (http://www.aalas.org/). Animal experiments were
approved by the Institutional Animal Care and Use Com-
mittee of Philip Morris Research Laboratories, Belgium or
Singapore (C57BL/6 study).
Although the studies were conducted at different times,
the smoke exposure conditions utilized in the studies were
largely conserved (Table 1). The Standard Reference Ci-
garette 3R4F was obtained from the Tobacco and Health
Institute at the University of Kentucky. It is a filter cigarette
with reported mainstream smoke yields per cigarette of
11.0 mg total particulate matter (TPM), 0.73 mg nicotine,
and 12.0 mg carbon monoxide (CO) (http://www2.ca.uky.
edu/refcig/3R4F%20Preliminary%20Analysis.pdf). All ci-
garettes were conditioned and smoked according to
International Organization for Standardization or Health
Canada Intense parameters [28, 30, 31]. Mainstream CS was
diluted with filtered conditioned air to a target concentration
of 750 mg TPM/m3, unless otherwise noted (Table 1).
The C57BL/6 study was conducted as a seven-month
smoke inhalation study using female C57BL/6 mice ap-
proximately 8–9 weeks of age at study commencement.
Mice (eight per group) were exposed in whole-body
chambers to diluted mainstream CS at a target concentra-
tion of 750 mg TPM/m3 for 4 h per day, 5 days per week,
with intermittent exposure to fresh filtered air for 30 min
after the first hour of smoke exposure and for 60 min after
the second and third exposure hours to avoid a build-up of
excessive carboxyhemoglobin (COHb) concentrations. An
initial 2-week concentration adaptation period was imple-
mented. Sham control animals were exposed to conditioned
fresh air. Dissection was performed at the end of the
scheduled exposure periods (1, 3, 5, and 7 months),
18–24 h after the last exposure. Lungs were snap-frozen,
and for each lung tissue sample, 22 slices (each 20 lm)
were cut using a cryostat and RNA was extracted, pro-
cessed, and analyzed as previously described [25, 32].
The A/J mouse study [25] was conducted as a 5-month
CS inhalation study using female A/J mice approximately
10–15 weeks of age at study commencement. Mice were
exposed to diluted mainstream CS at a target concentration
of 750 mg TPM/m3 for 4 h/day. After 5 months, lung
parenchyma and airway samples were collected using
laser-capture microdissection as described [33] from CS-
exposed mice and sham control mice exposed to condi-
tioned fresh air. The presence of emphysema was
histologically confirmed.
The ApoE-/- mouse study [28] was conducted as a six-
month CS inhalation study using female ApoE-/- mice
approximately 5–9 weeks of age at study commencement.
Animals were exposed to diluted mainstream CS at a target
concentration of 600 mg TPM/m3. Following 6 months of
exposure, whole lung and isolated parenchyma were col-
lected from CS-exposed mice and sham control mice
exposed to conditioned fresh air. The presence of emphy-
sema was histologically confirmed.














Age at start (weeks) *8–9 *5–9 *10–15 *12–13
Treatment Fresh air/3R4F Fresh air/3R4F Fresh air/3R4F Fresh air/2R4F
Exposure duration
Hours/day 4 3 4 4
Days/week 5 5 5 5
Months 1, 3, 5, 7 6 5 5




ISO 3308 ISO 3308
Concentration (mg TPM/m3) 750 600 750 750
Origin of gene expression data Whole lung Whole lung or lung
parenchyma
Lung parenchyma Whole lung
References Hoeng et al. [27] and
unpublished
Boue et al. [28] Xiang et al. [25] and
unpublished
Gebel et al. [29]










ApoE apolipoprotein E, Nrf2 nuclear factor, erythroid-derived 2, like 2
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The Nrf2-/- study [34] was conducted as a 5-month
smoke exposure study using both female Nrf2-/- mice and
wild-type littermates on the CD1 background that were
approximately 12–13 weeks of age at study commence-
ment. Animals were exposed to diluted mainstream CS at a
target concentration of 750 mg TPM/m3 for 4 h/day,
5 days per week. Whole lung samples were collected after
a 5-month CS-exposure. The presence of emphysema was
histologically confirmed.
Reverse causal reasoning
RCR interrogates a literature-based Knowledge Assembly
Model (KAM; a collection of biological concepts and en-
tities, and their causal relationships), to identify upstream
controllers of gene expression changes (so called State
Changes) observed in the transcriptomic data set [26]. For
all of the data set analysis, the full Selventa Knowledge-
base consisting of causal connections curated from
multiple species and contexts (e.g. human, mouse, and rat)
served as the KAM to interrogate the State Changes. The
potential upstream controllers identified by RCR are ter-
med ‘‘hypotheses’’ (HYPs) and are statistically significant
potential explanations for observed mRNA State Changes.
Each HYP is scored according to two probabilistic metrics,
richness and concordance. Richness is the probability that
the number of observed mRNA State Changes connected to
a given HYP could have occurred by chance alone, cal-
culated using the hypergeometric distribution.
Concordance is the probability that the number of observed
mRNA State Changes connected to the HYP occur in the
proper direction as predicted in the KAM (e.g. increased or
decreased activity, or abundance of a node), when com-
pared to chance alone, calculated using the binomial
distribution. The HYPs with P\ 0.05 for richness and
concordance were considered statistically significant.
To highlight patterns of significance of the concordance
values over time or across mouse strains, common HYPs
were grouped using a hierarchical clustering approach. The
clustering was performed using the Euclidean distance as
dissimilarity metrics calculated with the minus log10-
transformed concordance P values between each pair of
HYPs and the ‘‘median’’ as agglomerative method. The
minus log10-transformed concordance P values were mul-
tiplied by the sign of the concordance scores to provide the
directionality of regulation of the predicted upstream
controller (HYPs).
Lung histomorphometry
Alveolar emphysema was assessed by mean chord length
(Lm) measurements, as described previously [28]. Briefly,
several step serial sections per animal, representing a cross
section along the left main stem bronchus and its branching
bronchioles, was selected for morphometric evaluation. Lm
measurements were performed on images captured with an
Axio-Imager-Z1 microscope equipped with an 8-specimen
holder, a high-resolution digital color camera (Olympus
DP70) and VIS-software from Visiopharm (Horsholm,
Denmark). All measurements were conducted according to
Visiopharm’s quantitative digital pathology methods.
Bronchoalveolar lavage fluid (BALF) collection
and analysis
BALF was collected as previously described [28]. Cell-free
BALF supernatants were analyzed by Myriad Rules-Based
Medicine (Myriad RBM, Austin, TX, USA) using a Rodent
MAP 2.0 antibody arraywith 59 analytes/biomarkers (http://
rbm.myriad.com/products-services/rodentmap-services/
rodentmap/). Analyte measurements below the least de-
tectable dose (LDD) or the lower limit of quantification
(LLOQ) were substituted by max (LDD, LLOQ) and
divided by two. Six analytes (FGF-9, GST-alpha, IFN-
gamma, IL-17A, IL-3, and SGOT) were excluded from the
analysis since they were largely below the detection/quan-
tification limits.
Reverse phase protein array (RPPA) analysis
The TissueLyser II (Qiagen, Hilden, Germany) bead-mill
disruption system was used for protein extraction from cryo-
sliced right lung tissue samples, which were obtained from a
confirmatory follow-up study with the same exposure con-
ditions. Protein extraction was performed according to the
manufacturer’s instructions, using one 5-mm steel bead
(Qiagen) and 400 ll Zeptosens cell lysis buffer (CLB1,
Bayer Technology Services GmbH, Leverkusen, Germany).
After extraction, the sample was centrifuged in a micro-
centrifuge for 10 min at 14,000 rpm, and the cleared su-
pernatant was transferred into fresh tubes for further
analysis. Protein concentration of collected supernatants was
quantified as described [35] using a fluorescence-based
protein microspot assay [EZQTM Protein Quantitation Kit
(Life TechnologiesTM, Logan, UT, USA)]. Protein extracts
were stored at -80 C until further use.
Analysis of protein extracts by ZeptosensRPPA tech-
nology was performed as previously described [36].
Protein extracts were adjusted to uniform concentrations
with CLB1 buffer. Adjusted extracts were further diluted
with CLB1 buffer to a final spotting concentration of
0.1 lg/ll. Diluted extracts were printed at four serial di-
lutions (1.6-fold) onto Zeptosens hydrophobic chips
(Bayer Technology Services GmbH) using a microarray
printer (NanoPlotter 2.1, GeSiM, Grosserkmannsdorf,
Germany). Each sample was processed in technical
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duplicates with independent dilutions on separate arrays,
i.e. eight spots per sample with four spots per array. Fol-
lowing array printing, arrays were blocked, washed, and
dried according to the manufacturer’s specifications and
stored at 4 C in dark until further use.
For measurement of protein signals, arrays were incubated
overnight at room temperature in primary antibodies at dilu-
tions of 1:500 in CAB1 assay buffer (Bayer Technology
Services GmbH). The following primary antibodies
were used: anti-BRCA1 (sc646, Santa Cruz Biotechnology,
Dallas, TX, USA), anti-C/EBPa (sc61, Santa Cruz Biotech-
nology), anti-C/EBPb (sc150, Santa Cruz Biotechnology),
anti-ITGB6 (sc15329, Santa Cruz Biotechnology), anti-PU.1
(LSC30679, LifeSpan BioSciences, Seattle, WA, USA), anti-
SOCS3 (04004,MerckMillipore,Darmstadt,Germany), anti-
STAT1 (9172, Cell Signaling Technologies, Danvers, MA,
USA), and anti-STAT1(Tyr701) (44376G, Life Technolo-
gies). Following washing, arrays were incubated for 2 h with
either Alexa647- (Life Technologies) or Dylight650- (Bio-
Rad AbD Serotec GmbH, Puchheim, Germany) labeled anti-
species secondary antibodies, at dilutions of 1:500. After
subsequent washing, stained arrays were imaged using an
array scanner (ZeptoREADER, Bayer Technology Services
GmbH), according to the manufacturer’s recommendations.
For correction of anti-species secondary antibody staining,
arrays were assayed in the absence of primary antibodies. For
measurement of spotted protein amounts, one blank chip (i.e.
without antibody incubation) was stained with SYPRORu-
by. Scanned images were analyzed using ZeptoVIEW 3.1
software (Bayer Technology Services GmbH). Normalized
fluorescence intensities (NFI) for each sample and protein
target were calculated as reference fluorescence intensities of
primary antibody stained arrays (RFIprimary) corrected for
secondary antibody staining (RFIsecondary), as well as rela-
tive spotted protein concentration (RFIprotein), determined
by (RFIprimary–RFIsecondary)/RFIprotein, using the Zepto
VIEW 3.1 software. NFI values were used for subsequent
analysis.
Statistical analysis
For BALF analysis (MAP), RPPA, and histomorphometry,
two-tailed t tests were performed, assuming unequal
variance.
Results
Identification of potential mechanistic explanations
of CS-induced emphysema
To determine the molecular mechanisms underlying CS-
induced lung emphysema, we applied RCR to
transcriptomic data sets derived from lungs of five mouse
genotypes (C57BL/6, ApoE2/2, A/J, Nrf22/2 and CD1),
susceptible to emphysema development following a pro-
longed (5–6 months) exposure to CS. We and others have
already demonstrated that exposure to CS leads to in-
creased mean chord length (Lm) in CD1 (12.5 %), Nrf2-/-
(16 %), and ApoE-/- (17.1 %) mice [19, 28, 29]. In ad-
dition, long-term exposure to CS (5 months) resulted in
significant increase in the Lm in A/J (14 %) and C57BL/6
(44.9 %) mice (Fig. 1).
As described previously, RCR is a computational
methodology that uses a set of differentially measured
biological entities (e.g. mRNA) as inputs to make predic-
tions (called ‘‘HYPs’’) about the identity of potential
upstream controllers of observed differential measurements
[26]. For example, HYPs can refer to biological entities
such as protein abundance, regulatory mechanisms such as
activities of receptors, transcription factors, or kinases. By
comparing six data sets, we identified 39 predicted HYPs
that were conserved across five genotypes (Fig. 2, Supple-
mentary File 1). Another 37 common HYPs
(Supplementary File 1) were also predicted to be regulated.
They were related to biological processes (e.g. Natural
killer cell activation, T-helper 2 cell differentiation) or were
proxies that represented mechanisms using experimental
perturbations (Ovalbumin, Sirolimus, Bleomycin, etc.), and
were not currently considered for the experimental verifi-
cation. Out of the selected HYPs related to biological
entities, 28 were predicted to increase, and 11 predicted to
decrease. The majority of HYPs were related to the in-
flammatory response and mapped to nine sub-networks,
lung-specific Inflammatory Process Network model [37]
and Tissue Repair and Angiogenesis Network model [38],
consisting of the following submodels: Tissue Damage,
Neutrophil Response and Chemotaxis, Mucus Hypersecre-
tion, Macrophage Mediated Recruitment, Macrophage









































Fig. 1 Mean chord length (Lm) in C57BL/6 (left) and A/J (right)
mice exposed to fresh air (sham) or cigarette smoke (3R4F) for
5 months. Individual values are presented (n = 10–17 per group).
The exposure regime is described in ‘‘Materials and methods’’.
*P B 0.05 (3R4F vs. sham)
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Regulation of Angiogenesis, Epithelial Proinflammatory
Signaling, and Dendritic Cell Activation (Table 2). More
specifically, among the common HYPs, we identified in-
creased protein abundance of inflammatory mediators
associated with T helper (Th) responses [e.g.TNF-a, IFN-c,
IL-1b, colony stimulating factor (CSF)-2, IL-13, IL-17A,
and IL-17F]; increased activity of inflammation-related TFs
[e.g. NF-jB, STAT-1, Sfpi1 (known as PU.1)], C/EBP
family members a, b, and d; and increased receptor activity
of CCR3 and Toll-like receptors (TLRs)3 and 4.
Time-course of the occurrence of common
mechanisms in C57BL/6 mice
Since the comparative RCR analysis was performed cross-
sectionally on data sets derived from lungs with fully
developed emphysema, i.e. at the five-month time-point,
we investigated longitudinally the time-course of these
commonly identified HYPs as disease-related mechanisms
in one strain, i.e. the C57BL/6, from months one to seven.
To elucidate whether the predicted mechanisms might be
associated with the onset of destructive lung lesions, we
analyzed transcriptomic data sets obtained from lungs of
air- or smoke-exposed C57BL/6 mice at early time points
(months 1 and 3) preceding and accompanying the occur-
rence of observable anatomic changes associated with
emphysema ([21, 39] and unpublished data). Nearly all the
HYPs identified in the emphysematous lungs (at
5–6 months) were already statistically significant after the
first month of CS exposure (Fig. 3, Supplementary Fig-
ure 1), suggesting they could be linked to emphysema
onset and progression. Moreover, the majority of HYPs
Fig. 2 Common HYPs across
five mouse models exposed to
cigarette smoke for 5–6 months.
Results are shown as
hierarchically clustered color-
coded heatmap according to
HYP concordance and richness
(3R4F/2R4F vs. sham
comparison is shown). Yellow-
orange to blue gradient
indicates predicted increase and
decrease in abundance or
activity of HYPs. Catof,
catalytic activity of; kaof,
kinase activity of; taof,
transcriptional activity of; paof,
phosphatase activity of; gtpof,
GTP-binding activity of. L—
whole lung, P—lung
parenchyma (prepared by laser
capture microdissection) (color
figure online)
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(including increased catalytic activity of TLRs, transcrip-
tional activity of NF-jB, PU.1 and C/EBP, and protein
abundance of IFN-c, CSF2, IL-1b, and TNF-a) remained
significantly predicted over the course of CS exposure.
Some HYPs, however, such as receptor activity of CCR3
and CCR7, transcriptional activity of C/EBPa and STAT1,
and increased protein expression of BRCA1, CASP4, and
MyD88 were statistically significant from month 3 onwards
of CS exposure. Other HYPs were significant at early time
points and not at later time points, namely transcriptional
activity of YY1 and protein abundance of IL-20. Phos-
phatase activity of phosphatase and tensin homolog
(PTEN) remained significant with up to 7 months of CS
exposure, when compared with fresh air-exposed mice. In
the case of suppressor of cytokine signaling (SOCS)-3,
ITGB6, and CFTR, predicted decrease in their protein
expression persisted over time.
Proteomic analysis of selected HYPs in C57BL/6
mice
Next, we applied two targeted proteomic approaches to
further explore our findings using lungs of C57BL/6 mice
exposed to fresh air or 3R4F for up to 7 months. BALF was
analyzed with multiplexed bead arrays (Fig. 4a, b),
whereas RPPA was applied to lung tissue homogenates
from a follow-up study with the same design (Fig. 4c). For
RCR predictions reflecting inflammatory mediator protein
abundance, we confirmed that BALF levels of TNF-a, Il-
1b, CSF2 (Fig. 4a), and other ‘‘non-HYP’’ inflammatory
mediators including several interleukins, myeloperoxidase
(MPO), and matrix-metalloproteinase-9 (MMP-9) (Fig. 4b)
were increased upon CS exposure. Protein abundances
particularly related to six transcriptional activity-type
HYPs were analyzed in lung homogenates by measuring
increased protein abundance and phosphorylation levels
(Fig. 4c). We applied this approach based on the assump-
tion that regulatory activity (such as DNA-binding ability)
of a TF strongly depends on its protein abundance [40, 41].
We observed increased protein levels of BRCA1, C/EBPa,
C/EBPb, PU.1, and STAT1, thereby confirming the com-
putationally predicted protein candidates; however, we did
not detect increased tyrosine (Tyr705) phosphorylation
levels of STAT1 that would further indicate its transcrip-
tional activation. In contrast to RCR predictions, SOCS3
protein expression was increased, whereas MyD88 and
ITGB6 protein abundances were not affected by CS ex-
posure (Fig. 4c).
Discussion
In this study, we employed RCR on whole-genome tran-
scriptomic data sets to computationally predict molecular
mechanisms associated with the development of an em-
physematous phenotype in mouse models of disease. We
predicted 39 HYPs that may represent molecular mechan-
isms associated with the development of CS-induced
Table 2 Common HYPs mapped to subnetworks of the Inflammatory Process Network. Presence of a HYP within a specific subnetwork is
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emphysema. These HYPs were conserved across five sus-
ceptible mouse models (C57BL/6, ApoE2/2, A/J, CD1,
and Nrf22/2), suggesting that a core set of biological
features may be closely related to emphysema development
in a mouse model and may potentially be translatable to
human disease. Encouragingly, we verified various well-
known mechanistic changes associated with emphysema
development, such as NF-jB signaling and TLR4 signal-
ing, as well as increased levels of TNF-a, CSF2, and non-
predicted but related interleukins, MPO, and MMP-9 by
means of proteomic analysis. Even more importantly, we
identified several novel molecular mechanisms, such as
increased transcriptional activity of PU.1, STAT1, C/EBP,
FOXM1, and YY1, decreased activity of N-COR1, and
reduced protein abundance of ITGB6 and CFTR which
have been implicated in disease progression but have not
been comprehensively studied in this context, and can be
investigated further by targeted experiments. Of note, a
large proportion of the HYPs were related to inflammatory
processes as outlined in Fig. 5, consistent with the current
general concept that an abnormal inflammatory response is
a crucial pathological mechanism in the development of
CS-induced emphysema [42–44].
Transcription factors
Transcriptional regulators of inflammatory genes including
those related to cytokines, adhesion molecules, enzymes
and receptors, is part of the molecular signaling that drives
the development and progression of lung pathologies such
as asthma and COPD [45, 46]. Therefore, not surprisingly,
we predicted increased activation of TFs with well-known
roles in emphysema development, such as NF-jB [10, 45,
47–52], but we also revealed TFs with less described or
unknown roles in the etiology of emphysema.
For instance, we predicted increased transcriptional ac-
tivity of C/EBP family members (a, b, and d) and detected
increased abundance (which may be consistent with an
effective increase in transcriptional activity) of C/EBPa
and b proteins following smoke exposure. The C/EBP
family members are key transcriptional regulators of cell
differentiation, proliferation, apoptosis, and inflammatory
responses [53–55]. Although the binding activity of
C/EBPb, and to a lesser extent of C/EBPa, was enhanced
in smokers compared with never-smokers, their role in
emphysema remains undefined. It has been hypothesized
that CS-increased C/EBP activity serves as a protective
Fig. 3 Time course of the
occurrence of common HYPs in
C57BL/6 mice exposed to
cigarette smoke (3R4F) for up
to 7 months. Results are shown
as hierarchically clustered
color-coded heatmap according
to HYP concordance and
richness (3R4F vs. sham
comparison is shown). Yellow-
orange to blue gradient
indicates predicted increase and
decrease in abundance or
activity of HYPs. Catof,
catalytic activity of; kaof,
kinase activity of; taof,
transcriptional activity of; paof,
phosphatase activity of; gtpof,
GTP-binding activity of. Note:
For an easier tracking of the
common HYPs from the strain
comparison (Fig. 2) and from
the temporal development in
one strain (Fig. 3), a side-by-
side comparison in alphabetical
order of all HYPs from both
heatmaps has been provided in
Supplementary Figure 1 (color
figure online)
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mechanism by stimulating lung epithelial regeneration
through promotion of cell proliferation, inhibition of
apoptotic signals, and activation of inflammatory genes
[53]. In mice, lung epithelial-specific inactivation of
C/EBPb resulted in impaired CS-induced neutrophil re-
cruitment to the lung and compromised induction of
neutrophil chemoattractants, but its contribution to em-
physema is unclear, in particular because the mRNA levels
of C/EBPb were down-regulated in the airway epithelium
of smokers [56], which is difficult to align with the pre-
vious findings from the same group that the C/EBP binding
activities were increased in the lung tissue from healthy
smokers but not from COPD and chronic bronchitis pa-
tients [53]. Our results, together with the known role of
C/EBPs in controlling expression of genes encoding in-
flammatory cytokines, and proteinases, suggest C/EBP
family members as important players in the pathogenesis of
emphysema [53, 54, 57].
We also predicted increased activity of PU.1, a TF se-
lectively expressed in hematopoietic tissues, which plays a
critical role in development, maturation, and function of
lymphoid and myeloid cells such as macrophages [58].
Indeed, PU.1 is required for many functions performed by
alveolar macrophages, including phagocytosis, MMP
Fig. 4 Proteomic analysis of selected HYPs in C57BL/6 mice
exposed to fresh air (sham) or cigarette smoke (3R4F) for up to
7 months. C57BL/6 mice were exposed as described in ‘‘Materials
and methods’’ and killed 18–24 h after the last exposure. (a) Levels of
BALF inflammatory mediators were measured using multiplexed
bead array as described in ‘‘Materials and methods’’. Values of
selected inflammatory mediators are presented as single measure-
ments and as mean ± SD (n = 8–10 per group). *P B 0.05; (3R4F
vs. sham). Blue stars and lines sham; red diamonds and lines 3R4F;
gray dotted line limit of detection/quantification (b) Heatmap repre-
sentation of all regulated inflammatory mediators from the BALF
analysis. The color coding indicates the Log2 ratio of protein
abundance (3R4F vs. sham); *P B 0.05. (c) Protein abundance in
lung homogenates was measured using RPPA as described in
‘‘Materials and methods’’ (n = 10 per group). Results are shown as
ratios of abundance (3R4F/Sham) and color-coded heatmap reflecting
statistical significance (color figure online)
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expression, reactive oxygen species production, surfactant
catabolism, and secretion of pro-inflammatory cytokines
[58] and lipoxygenase, which is implicated in asthma,
atherosclerosis, and arthritis [59]. In addition, PU.1 has
been shown to regulate expression and activity of emphy-
sema-associated proteolytic enzymes such as cathepsin S
and neutrophil elastase (NE) [60, 61]. Our results suggest
that the activity of PU.1 may play a significant role in the
development and progression of emphysema due to its
maximal statistical enrichment occurring at month 5
(Fig. 3), corresponding to the time course of increasing
emphysematous changes in the C57BL/6 model [62].
Furthermore, its activity is even more pronounced in other
mouse strains (e.g. Nrf2-/-) at the month-5 time point,
suggesting an even more significant role in the process of
emphysema development (Fig. 2).
STAT1 is a known inducer of emphysema-associated
processes such as apoptosis and inflammation; however, its
precise role in emphysema and COPD development has not
been established. Recently it has been demonstrated that
STAT1 protein abundance is augmented in emphysematous
lungs of gp130F/F mice, although without significant
changes in its tyrosine phosphorylation [63]. In addition,
exposure of bronchial cells to CS extracts resulted in in-
creased STAT1 phosphorylation and binding to the
promoter regions of intercellular adhesion molecule
(ICAM)-1, a mechanism that may contribute to airway
neutrophilia and tissue damage [64]. STAT1 phosphory-
lation levels are increased in sputum from COPD patients,
which induces oxidative and nitrosative stress in 16-HBE
bronchial epithelial cells [65]. In bronchial biopsies from
COPD patients compared to asymptomatic smokers, more
Fig. 5 Possible interrelationships and roles for the identified common
mechanisms (HYPs) in five mouse models of emphysema in a
framework of classical human COPD mechanisms. The RCR-
predicted decreases (green arrows) and increases (red arrows) in
transcription factors (black font) and inflammatory mediators (orange
font) common to the investigated mouse models have been associated
with classical pathways of human COPD pathogenesis (black arrows)
as depicted, e.g., in recent reviews [98, 99] and in other relevant
articles mentioned in the ‘‘Discussion’’. Central predicted roles for
emphysema formation (on the right side) are assigned to the NFjB
signaling in epithelial cells and macrophages triggered by, e.g.,
TNFa, IL17, or activation of TLR3/4, resulting in the shedding of
TNFa, CSF2, Il1b, and MMPs. The predicted and measured
activation of STAT1- and PU.1 would (particularly in macrophages)
also be consistent with the recruitment and activation of neutrophils
that enhance emphysema by NE production. On the left side of the
scheme, the predicted decrease in NCOR1 activity in conjunction
with increased transcriptional activity of FOXM1 would be in
conformity with goblet cell activation involved in airway disease
(which in mouse models is less pronounced than in human COPD
patients). For further details, please refer to the ‘‘Discussion’’ (color
figure online)
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cells being positive for phosphorylated STAT1 have been
observed [66]. Results described here further support a
potential role of STAT1 in emphysema development.
We also predicted increased transcriptional activity of
FOXM1 which is a member of the forkhead box (Fox)
family of TFs that play important roles in cellular prolif-
eration, differentiation, and tumorigenesis [67]. Its role in
inflammation has been evaluated using a mouse model of
house dust mite allergen-induced allergic asthma. It has
been shown that conditional deletion of the Foxm1 gene
from either airway epithelium or myeloid inflammatory
cells decreased goblet cell metaplasia, reduced lung in-
flammation, and decreased airway resistance [68].
Moreover, the amount of FOXM1 protein was increased in
bronchiolar epithelium and in inflammatory cells isolated
from COPD patients [68], but no further studies were
performed to investigate the role of FOXM1 in CS-induced
emphysema in mice or humans. For YY1, we also pre-
dicted increased transcriptional activity predominantly at
the early time points and this effect was diminished at later
time points; so far, a role for this transcription factor in
COPD has been observed only in COPD-associated
skeletal muscle atrophy, but not in lung tissue [69]. No
association with COPD has been reported for NCOR1, a
co-repressor of PPAR d, c, and an antagonist of b-catenin
[70], but the known involvement of the Wnt b-catenin
pathway in abnormal airway responses in COPD patients
[71, 72] and the established protective role of PPARc ac-
tivation against COPD [73–75] warrant further
investigations related to the predicted activation of NCOR1
in COPD-susceptible mouse models.
Th1/Th2/Th17-type cytokines
A common characteristic of COPD is progressive lym-
phocyte infiltration into the small airways and alveolar
walls [76, 77]. In mice, CS-exposure induces lung re-
cruitment of CD4?, CD8?, and B cells, enhancing pro-
inflammatory Th1 cytokine production that might sig-
nificantly contribute to emphysema development [8].
Indeed, deletion of genes encoding the TNF-a receptor or
IFN-c protects mice from development of CS-induced
emphysema [78, 79], whereas TNF-a or IFN-c overex-
pression leads to lung emphysema [80–82]. In this regard,
using an RCR analysis and proteomic approach, we pre-
dicted and/or measured increased protein abundance over
time for Th1-associated cytokines such as TNF-a, IL-2,
and IFN-c in CS-exposed mice. At the same time, we
predicted increased protein levels of IL-13, a Th2 cytokine,
which may contribute to mucus hypersecretion and chronic
bronchitis in smokers and COPD patients [83, 84]. We also
measured increased abundance of the Th2 effector cy-
tokines IL-4, 5, 6, and 10. Although the mucus
hypersecretion response is not well recapitulated in rodents
[83], a direct role of IL-13 in CS-induced emphysema has
been demonstrated [60].
A large number of studies have shown that COPD is
largely associated with increased Th1 responses; however,
recent studies have proposed an important role for Th17
cells in the pathogenesis of COPD [85, 86]. In mice,
chronic exposure to CS has been shown to induce lung
recruitment of Th17 cells [87]. More recently, Chen et al.
[88] demonstrated that mice lacking the IL-17A receptor
(Il17Ra-/-) failed to develop emphysema after 6 months
of CS exposure. Likewise, IL-17 was essential for elastase-
induced emphysema formation and lung inflammation in
C57BL/6 mice [89]. In agreement with these data, we have
predicted increased abundance of the two IL-17 family
members, IL-17A and IL-17F, in emphysematous lungs,
with maximal inferred abundance peaking at the month-5
experimental time point, corresponding to the time course
of emphysematous changes and suggesting involvement in
the tissue destruction process.
Protease–antiprotease imbalance
Protease–antiprotease imbalance is regarded as a prevailing
mechanism in the development of mouse and human em-
physema [90]. Key events leading to lung extracellular
matrix degradation during this process involve inflamma-
tory cell recruitment into the lungs and the release of an
uncontrolled amount of proteases. Indeed, increased lung
concentrations of NE, MMP-1, MMP-9, and MMP-12 have
been found in CS-exposed mice and emphysema patients
[91], and thus excessive proteolytic activity must be tightly
regulated. Morris et al. [92] described an interesting
mechanism regulating MMP-12 activity, showing that
Itgb6-null mice lacking the b-subunit of the avb6 integrin,
an integrin abundantly expressed by bronchiolar and
alveolar epithelial cells, developed spontaneous age-related
MMP-12-dependent emphysema. In accordance, we pre-
dicted reduced ITGB6 protein abundance as a potential
mechanism contributing to CS-induced emphysema; how-
ever, the measured ITGB6 protein abundance in lung
homogenates did not change as a result of CS exposure. We
can speculate that post translational modifications may
stabilize the integrin molecules at the sites of cell adhesion
and, therefore, a down-regulation of newly synthesized
ITGB6 as predicted will not necessarily translate into re-
duced amounts of total ITGB6 in the tissue; however,
further studies are necessary to explore the observed
discrepancy.
Our proteomic approach did not confirm RCR predic-
tions for decreased SOCS3 and increased MyD88 protein
abundances; however, considering their known role in in-
flammatory processes these mechanisms are potentially
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active. SOCS3 is an important negative regulator of in-
flammatory reactions, especially in IL-6-driven
pathological conditions [93]. Moreover, mice with he-
matopoietic cell-specific deletion of the Socs3 gene
developed neutrophilia and a variety of inflammatory
pathologies [94]. Thus, the predicted decrease of SOCS3
protein may significantly contribute to the observed pro-
gression of CS-induced pathologies (e.g. neutrophilia,
lung emphysema). We can speculate that RPPA-detected
increased SOCS3 protein levels in the whole lung tissue
may represent a compensatory mechanism to limit in-
flammation and/or SOCS3 protein degradation
mechanisms can be inhibited by CS. With regard to
MyD88, it serves as an essential adaptor protein in TLR
and IL1R signaling pathway [95], and MyD88 deficiency
leads to spontaneous emphysema [96]. On the other hand,
CS-induced neutrophilia was ablated in MyD88-deficient
mice [97].
Collectively, the RCR analysis of lung transcriptomic
data provides a robust approach for comparing and iden-
tifying molecular changes involved in the development of
CS-induced emphysema, which was also corroborated by
the independently measured protein abundances of selected
HYPs. Many of the common mechanistic features identi-
fied here are consistent with prevailing theories of disease
development in murine models of CS-induced emphysema,
as well as in the pathogenesis of human COPD, testifying
to the powerful predictive ability of the RCR approach in
assessing disease development and progression. The puta-
tive correspondence of predicted changes in transcription
factor activities and inflammatory mediator abundances
with classical mechanisms of COPD pathogenesis [98, 99]
has been depicted in Fig. 5. Furthermore, we extended our
analysis to identify a series of novel molecular mechanisms
with potentially causative roles in emphysema develop-
ment for further exploration. In conclusion, a systems
toxicology approach, including histopathology, transcrip-
tomics, proteomics, and computational hypothesis
generation, has been applied to investigate the molecular
mechanisms of CS-induced emphysema in a variety of
susceptible mouse strains. Clearly, further studies to
functionally validate our predictions are needed; however,
the results of our meta-analysis open new vistas to obtain
more detailed insights into the pathogenic mechanisms of
emphysema, and of COPD in general.
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